Kwok Lisa, Boucher Michel
Issues Emerg Health Technol. 2004 Jun(57):1-4.
Ximelagatran (Exanta (TM)) is the first oral agent in a new class of anticoagulants called direct thrombin inhibitors. Most of the available evidence regarding venous thromboembolism is from studies focusing on its prevention after major orthopedic surgery. Ximelagatran's efficacy is comparable to that of warfarin and low-molecular-weight heparin in this setting. The rates of bleeding complications for ximelagatran and its comparators were not statistically different. The elevation of liver enzymes was observed in longer term trials.
希美加群（Exanta™）是新型抗凝剂类中的首个口服制剂，这类抗凝剂被称为直接凝血酶抑制剂。关于静脉血栓栓塞的现有证据大多来自专注于大型骨科手术后预防的研究。在这种情况下，希美加群的疗效与华法林和低分子肝素相当。希美加群及其对照药物的出血并发症发生率在统计学上无差异。在长期试验中观察到了肝酶升高的情况。
